Importance

Loading Importance Indicators...

Abstract

A first aspect of the invention relates to a compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in treating a proliferative disorder, wherein: X is NR⁷; R¹ and R² are each independently H, alkyl or cycloalkyl; R³ is a 6-membered heterocycloalkyl group selected from piperidinyl, piperazinyl, morpholinyl and tetrahydropyranyl, wherein said heterocycloalkyl group is optionally further substituted by one or more (CH₂)—R¹⁹ groups; R⁴ and R^4′ are each independently H or alkyl; or R⁴ and R^4′ together form a spiro cycloalkyl group; Q is CH or N; R⁶ is OR⁸ or halogen; n is 1, 2 or 3; R¹⁹ is H, alkyl, aryl or a cycloalkyl group; R⁷ and R⁸ are each independently H or alkyl; and wherein said compound is administered in accordance with a dosing regimen which: (i) maintains a plasma concentration of from about 50 to about 500 nM for a period of up to about 16 hours; or (ii) maintains a plasma concentration of from about 0.5 μM to about 1 μM for a period of up to about 6 hours; or (iii) achieves a maximum plasma concentration (Cmax) of no more than about 500 nM within a period of about 6 hours; or (iv) achieves a maximum plasma concentration (Cmax) of no more than about 200 nM within a period of about 16 hours; or (v) achieves a maximum plasma concentration (Cmax) of about 0.5 μM to about 1 μM within about 6 hours. Further claims relate to a method of treatment based on this dosing regimen, and kits relating to the same.

Loading the Abstract Image...

First Claim